| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 23 | 2022 | 340 | 5.580 |
Why?
|
| Arteriovenous Shunt, Surgical | 12 | 2019 | 70 | 3.760 |
Why?
|
| Kidney Failure, Chronic | 14 | 2022 | 416 | 3.720 |
Why?
|
| Renal Insufficiency, Chronic | 5 | 2022 | 237 | 1.950 |
Why?
|
| Kidney Transplantation | 5 | 2022 | 863 | 1.610 |
Why?
|
| Central Venous Catheters | 3 | 2016 | 21 | 1.500 |
Why?
|
| Catheterization, Peripheral | 4 | 2017 | 62 | 1.480 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 2 | 2022 | 144 | 1.370 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2019 | 227 | 1.040 |
Why?
|
| Neuromuscular Junction | 3 | 2015 | 78 | 1.040 |
Why?
|
| Drosophila | 5 | 2015 | 526 | 0.960 |
Why?
|
| Catheterization, Central Venous | 2 | 2017 | 115 | 0.940 |
Why?
|
| Graft Rejection | 2 | 2021 | 1110 | 0.900 |
Why?
|
| Drosophila Proteins | 7 | 2015 | 513 | 0.790 |
Why?
|
| Peritoneal Dialysis | 2 | 2020 | 31 | 0.790 |
Why?
|
| Immunosuppressive Agents | 3 | 2019 | 989 | 0.790 |
Why?
|
| Cystatin C | 1 | 2022 | 28 | 0.780 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2021 | 22 | 0.760 |
Why?
|
| Graft Survival | 3 | 2021 | 935 | 0.680 |
Why?
|
| Biological Variation, Individual | 1 | 2019 | 7 | 0.650 |
Why?
|
| Presynaptic Terminals | 2 | 2015 | 41 | 0.650 |
Why?
|
| Transplant Recipients | 1 | 2021 | 152 | 0.650 |
Why?
|
| Aged | 22 | 2022 | 19943 | 0.640 |
Why?
|
| Transitional Care | 1 | 2019 | 17 | 0.640 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 36 | 0.630 |
Why?
|
| Drug Monitoring | 1 | 2019 | 116 | 0.610 |
Why?
|
| Tacrolimus | 2 | 2019 | 373 | 0.600 |
Why?
|
| Male | 32 | 2022 | 43925 | 0.600 |
Why?
|
| Middle Aged | 26 | 2022 | 27030 | 0.600 |
Why?
|
| Patient Transfer | 1 | 2019 | 103 | 0.590 |
Why?
|
| Female | 32 | 2022 | 47893 | 0.590 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2009 | 99 | 0.580 |
Why?
|
| Inpatients | 2 | 2015 | 331 | 0.580 |
Why?
|
| Body Mass Index | 1 | 2021 | 800 | 0.560 |
Why?
|
| Hemodialysis Solutions | 1 | 2017 | 2 | 0.550 |
Why?
|
| Vascular Grafting | 1 | 2016 | 17 | 0.520 |
Why?
|
| Treatment Outcome | 13 | 2021 | 8740 | 0.510 |
Why?
|
| Healthcare Disparities | 2 | 2022 | 444 | 0.510 |
Why?
|
| Upper Extremity | 2 | 2015 | 62 | 0.510 |
Why?
|
| Mycophenolic Acid | 2 | 2013 | 85 | 0.480 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 2 | 2013 | 4 | 0.480 |
Why?
|
| Humans | 43 | 2022 | 92337 | 0.470 |
Why?
|
| Pulmonary Embolism | 2 | 2009 | 230 | 0.460 |
Why?
|
| Obesity | 1 | 2021 | 1016 | 0.440 |
Why?
|
| Plasmapheresis | 1 | 2013 | 25 | 0.420 |
Why?
|
| Catheters, Indwelling | 3 | 2008 | 113 | 0.410 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 456 | 0.410 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 743 | 0.410 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 451 | 0.410 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 760 | 0.400 |
Why?
|
| Aged, 80 and over | 9 | 2019 | 6916 | 0.370 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 64 | 0.360 |
Why?
|
| Adult | 17 | 2022 | 27532 | 0.360 |
Why?
|
| United States | 6 | 2022 | 7348 | 0.360 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 195 | 0.350 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 104 | 0.340 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 619 | 0.320 |
Why?
|
| Immunoglobulins | 2 | 2015 | 139 | 0.320 |
Why?
|
| Retrospective Studies | 9 | 2022 | 9703 | 0.310 |
Why?
|
| Acute Kidney Injury | 4 | 2008 | 324 | 0.310 |
Why?
|
| Hypertension | 2 | 2020 | 763 | 0.300 |
Why?
|
| Synapses | 2 | 2015 | 281 | 0.300 |
Why?
|
| Spironolactone | 2 | 2009 | 12 | 0.300 |
Why?
|
| Fumarates | 1 | 2008 | 20 | 0.300 |
Why?
|
| Amides | 1 | 2008 | 55 | 0.290 |
Why?
|
| Lower Extremity | 1 | 2009 | 93 | 0.290 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 98 | 0.290 |
Why?
|
| Thromboembolism | 1 | 2009 | 126 | 0.290 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 3775 | 0.270 |
Why?
|
| Thrombectomy | 1 | 2009 | 197 | 0.270 |
Why?
|
| Anticoagulants | 3 | 2009 | 443 | 0.270 |
Why?
|
| Paracentesis | 1 | 2006 | 9 | 0.270 |
Why?
|
| Embolism, Cholesterol | 1 | 2006 | 2 | 0.260 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2008 | 174 | 0.260 |
Why?
|
| Odds Ratio | 2 | 2020 | 694 | 0.260 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2006 | 4 | 0.260 |
Why?
|
| Fibrinolytic Agents | 1 | 2008 | 233 | 0.250 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 253 | 0.250 |
Why?
|
| Ulnar Artery | 1 | 2006 | 5 | 0.250 |
Why?
|
| Risk Assessment | 3 | 2019 | 2369 | 0.250 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 261 | 0.250 |
Why?
|
| Collateral Circulation | 1 | 2006 | 38 | 0.250 |
Why?
|
| Risk Factors | 4 | 2019 | 5704 | 0.250 |
Why?
|
| Creatinine | 2 | 2022 | 296 | 0.240 |
Why?
|
| Aortic Diseases | 1 | 2006 | 102 | 0.240 |
Why?
|
| Thrombosis | 1 | 2008 | 312 | 0.240 |
Why?
|
| Pennsylvania | 3 | 2015 | 99 | 0.240 |
Why?
|
| Protein Interaction Maps | 2 | 2015 | 53 | 0.240 |
Why?
|
| Time Factors | 4 | 2019 | 5430 | 0.240 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2006 | 111 | 0.240 |
Why?
|
| Vascular Patency | 2 | 2019 | 127 | 0.230 |
Why?
|
| Heparin | 1 | 2005 | 185 | 0.230 |
Why?
|
| Hemorrhage | 2 | 2008 | 291 | 0.230 |
Why?
|
| Ascites | 1 | 2004 | 57 | 0.230 |
Why?
|
| Neoplasms | 1 | 2020 | 3117 | 0.230 |
Why?
|
| Databases, Factual | 2 | 2019 | 955 | 0.220 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2003 | 20 | 0.220 |
Why?
|
| Hyperkalemia | 1 | 2003 | 18 | 0.210 |
Why?
|
| Bone Morphogenetic Proteins | 2 | 2015 | 132 | 0.210 |
Why?
|
| Fibronectins | 1 | 2013 | 102 | 0.200 |
Why?
|
| Potassium Channels | 1 | 2005 | 347 | 0.200 |
Why?
|
| Patient Selection | 2 | 2008 | 689 | 0.190 |
Why?
|
| Equipment Design | 3 | 2015 | 418 | 0.190 |
Why?
|
| Cohort Studies | 2 | 2021 | 2978 | 0.190 |
Why?
|
| Outpatients | 1 | 2022 | 106 | 0.190 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 105 | 0.180 |
Why?
|
| Receptors, Cell Surface | 3 | 2013 | 291 | 0.180 |
Why?
|
| Glomerular Filtration Rate | 1 | 2022 | 280 | 0.180 |
Why?
|
| Semaphorins | 1 | 2010 | 17 | 0.180 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 24 | 0.170 |
Why?
|
| Potassium | 2 | 2017 | 261 | 0.170 |
Why?
|
| Larva | 3 | 2015 | 124 | 0.170 |
Why?
|
| Calcium | 3 | 2022 | 1183 | 0.160 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2020 | 62 | 0.160 |
Why?
|
| Datasets as Topic | 1 | 2019 | 80 | 0.160 |
Why?
|
| Angioplasty | 1 | 2019 | 71 | 0.160 |
Why?
|
| Arteriovenous Fistula | 1 | 2019 | 54 | 0.150 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 618 | 0.150 |
Why?
|
| Prevalence | 2 | 2020 | 1294 | 0.150 |
Why?
|
| Polymyositis | 1 | 2018 | 6 | 0.150 |
Why?
|
| Postoperative Complications | 2 | 2006 | 2458 | 0.140 |
Why?
|
| Dermatomyositis | 1 | 2018 | 18 | 0.140 |
Why?
|
| Proteins | 1 | 2013 | 803 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2009 | 3509 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2020 | 282 | 0.140 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 72 | 0.140 |
Why?
|
| Bicarbonates | 1 | 2017 | 58 | 0.130 |
Why?
|
| Appendicitis | 1 | 2017 | 73 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2018 | 275 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 963 | 0.130 |
Why?
|
| Animals | 9 | 2015 | 28003 | 0.130 |
Why?
|
| Magnesium | 1 | 2017 | 177 | 0.130 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 359 | 0.130 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2013 | 668 | 0.130 |
Why?
|
| Renin | 2 | 2008 | 67 | 0.130 |
Why?
|
| Comorbidity | 1 | 2020 | 987 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2017 | 159 | 0.120 |
Why?
|
| Sodium | 1 | 2017 | 335 | 0.120 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2015 | 17 | 0.120 |
Why?
|
| Biomarkers | 1 | 2022 | 1850 | 0.120 |
Why?
|
| Catheterization | 2 | 2007 | 238 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 267 | 0.120 |
Why?
|
| Second Messenger Systems | 1 | 2015 | 43 | 0.120 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 66 | 0.120 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2015 | 88 | 0.120 |
Why?
|
| Acyltransferases | 1 | 2015 | 52 | 0.120 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 276 | 0.110 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 871 | 0.110 |
Why?
|
| Hospitals, Teaching | 1 | 2015 | 118 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2015 | 286 | 0.110 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2018 | 281 | 0.110 |
Why?
|
| Blood Flow Velocity | 2 | 2019 | 199 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2017 | 501 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 430 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2015 | 1079 | 0.110 |
Why?
|
| HTLV-I Infections | 1 | 2013 | 5 | 0.110 |
Why?
|
| Strongyloidiasis | 1 | 2013 | 6 | 0.110 |
Why?
|
| Meningitis, Bacterial | 1 | 2013 | 14 | 0.110 |
Why?
|
| Sex Factors | 1 | 2017 | 1095 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 152 | 0.110 |
Why?
|
| Program Evaluation | 1 | 2015 | 315 | 0.100 |
Why?
|
| Medicare | 1 | 2017 | 440 | 0.100 |
Why?
|
| Organs at Risk | 1 | 2013 | 46 | 0.100 |
Why?
|
| Bone Morphogenetic Protein Receptors | 1 | 2013 | 6 | 0.100 |
Why?
|
| Fertility Preservation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Logistic Models | 1 | 2017 | 1239 | 0.100 |
Why?
|
| Vitiligo | 1 | 2013 | 17 | 0.100 |
Why?
|
| Guideline Adherence | 1 | 2015 | 239 | 0.100 |
Why?
|
| Graves Disease | 1 | 2013 | 36 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1939 | 0.100 |
Why?
|
| Animals, Genetically Modified | 2 | 2010 | 184 | 0.100 |
Why?
|
| Prognosis | 2 | 2018 | 3872 | 0.100 |
Why?
|
| Survival Rate | 1 | 2016 | 1927 | 0.100 |
Why?
|
| Medical Tourism | 1 | 2011 | 5 | 0.100 |
Why?
|
| Hand | 1 | 2013 | 145 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2013 | 278 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2013 | 3508 | 0.090 |
Why?
|
| Protein Binding | 1 | 2015 | 1513 | 0.090 |
Why?
|
| Cadaver | 1 | 2011 | 191 | 0.090 |
Why?
|
| Leishmania | 1 | 2001 | 7 | 0.090 |
Why?
|
| Cyclosporine | 2 | 2007 | 241 | 0.090 |
Why?
|
| RNA Editing | 1 | 2001 | 35 | 0.090 |
Why?
|
| Stroke | 1 | 2020 | 1038 | 0.090 |
Why?
|
| Postoperative Care | 1 | 2011 | 239 | 0.090 |
Why?
|
| Adolescent | 3 | 2018 | 9504 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1774 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2015 | 358 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2015 | 1240 | 0.080 |
Why?
|
| Brachial Artery | 1 | 2009 | 37 | 0.080 |
Why?
|
| Veins | 1 | 2009 | 96 | 0.070 |
Why?
|
| Equipment Contamination | 1 | 2008 | 26 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2009 | 77 | 0.070 |
Why?
|
| Biofilms | 1 | 2008 | 47 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2011 | 531 | 0.070 |
Why?
|
| Biological Availability | 1 | 2008 | 91 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 109 | 0.070 |
Why?
|
| Prednisolone | 1 | 2007 | 41 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 173 | 0.070 |
Why?
|
| Neurons | 1 | 2015 | 1596 | 0.070 |
Why?
|
| Tissue and Organ Procurement | 1 | 2011 | 380 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2006 | 32 | 0.070 |
Why?
|
| Women's Health | 1 | 2007 | 105 | 0.070 |
Why?
|
| Hemoptysis | 1 | 2006 | 24 | 0.070 |
Why?
|
| Administration, Oral | 1 | 2008 | 673 | 0.070 |
Why?
|
| Amino Acid Sequence | 2 | 2015 | 2074 | 0.060 |
Why?
|
| Shock | 1 | 2006 | 44 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2019 | 4468 | 0.060 |
Why?
|
| Albumins | 1 | 2006 | 134 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 186 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 807 | 0.060 |
Why?
|
| Radial Artery | 1 | 2006 | 36 | 0.060 |
Why?
|
| Stomach | 1 | 2006 | 111 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 299 | 0.060 |
Why?
|
| Kidney | 2 | 2006 | 1145 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2005 | 24 | 0.060 |
Why?
|
| Organizational Culture | 1 | 2005 | 35 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2005 | 30 | 0.060 |
Why?
|
| Spleen | 1 | 2006 | 435 | 0.060 |
Why?
|
| Kidney Calculi | 1 | 2008 | 343 | 0.060 |
Why?
|
| Critical Care | 1 | 2008 | 399 | 0.060 |
Why?
|
| Japan | 2 | 2017 | 306 | 0.060 |
Why?
|
| Shaker Superfamily of Potassium Channels | 1 | 2005 | 50 | 0.060 |
Why?
|
| Platelet Count | 1 | 2004 | 92 | 0.060 |
Why?
|
| Nephrology | 1 | 2005 | 44 | 0.060 |
Why?
|
| Acute Disease | 1 | 2006 | 856 | 0.060 |
Why?
|
| Serum Albumin | 1 | 2004 | 127 | 0.060 |
Why?
|
| Respiratory Insufficiency | 1 | 2006 | 183 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 887 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 795 | 0.050 |
Why?
|
| Aldosterone | 1 | 2003 | 56 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2005 | 294 | 0.050 |
Why?
|
| Endocarditis | 1 | 2003 | 22 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2352 | 0.050 |
Why?
|
| Ligands | 1 | 2013 | 457 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 84 | 0.050 |
Why?
|
| Behavior, Animal | 1 | 2005 | 385 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2013 | 741 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2022 | 222 | 0.050 |
Why?
|
| Liver | 1 | 2006 | 1228 | 0.050 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2010 | 30 | 0.040 |
Why?
|
| Calcium Channels, N-Type | 1 | 2010 | 17 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2002 | 154 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2004 | 909 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 542 | 0.040 |
Why?
|
| Muscles | 1 | 2010 | 190 | 0.040 |
Why?
|
| Vitamin D | 1 | 2022 | 269 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 657 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 1 | 2010 | 196 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2010 | 371 | 0.040 |
Why?
|
| Lung | 1 | 2006 | 1337 | 0.040 |
Why?
|
| Kidneys, Artificial | 1 | 2019 | 4 | 0.040 |
Why?
|
| Motor Neurons | 1 | 2010 | 168 | 0.040 |
Why?
|
| Brachiocephalic Veins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 83 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3017 | 0.040 |
Why?
|
| Phenotype | 1 | 2005 | 2498 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2002 | 374 | 0.040 |
Why?
|
| Aspirin | 1 | 2019 | 163 | 0.040 |
Why?
|
| Interferon-Induced Helicase, IFIH1 | 1 | 2018 | 11 | 0.040 |
Why?
|
| Amino Acyl-tRNA Synthetases | 1 | 2018 | 14 | 0.040 |
Why?
|
| Somatosensory Disorders | 1 | 2017 | 3 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2018 | 126 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 507 | 0.040 |
Why?
|
| Phylogeny | 1 | 2013 | 1228 | 0.030 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 246 | 0.030 |
Why?
|
| Action Potentials | 1 | 2010 | 604 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2010 | 550 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 6624 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 203 | 0.030 |
Why?
|
| Streptococcus bovis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Coinfection | 1 | 2013 | 63 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 1902 | 0.030 |
Why?
|
| Age Factors | 1 | 2017 | 1905 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2013 | 217 | 0.020 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (GTP) | 1 | 1991 | 8 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1336 | 0.020 |
Why?
|
| RNA, Protozoan | 1 | 2001 | 5 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 1991 | 92 | 0.020 |
Why?
|
| Uridine | 1 | 2001 | 58 | 0.020 |
Why?
|
| Protozoan Proteins | 1 | 2001 | 74 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2001 | 351 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2001 | 247 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2001 | 515 | 0.020 |
Why?
|
| Convection | 1 | 2008 | 11 | 0.020 |
Why?
|
| Mutation | 1 | 2010 | 4204 | 0.020 |
Why?
|
| Dialysis Solutions | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hypothermia | 1 | 2008 | 26 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2008 | 118 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 91 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2001 | 2037 | 0.020 |
Why?
|
| Equipment Failure | 1 | 2008 | 123 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 1163 | 0.020 |
Why?
|
| Mitochondria | 1 | 2001 | 599 | 0.020 |
Why?
|
| RNA | 1 | 2001 | 589 | 0.020 |
Why?
|
| Critical Illness | 1 | 2008 | 328 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2008 | 756 | 0.010 |
Why?
|
| Sepsis | 1 | 2008 | 350 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1991 | 311 | 0.010 |
Why?
|
| Gene Expression | 1 | 1991 | 1312 | 0.000 |
Why?
|
| Rats | 1 | 1991 | 4067 | 0.000 |
Why?
|
| Models, Biological | 1 | 1991 | 1786 | 0.000 |
Why?
|